Stable IL-10: a new therapeutic that promotes tumor immunity

Michele W L Teng; Phillip K Darcy; Mark J Smyth

doi:10.1016/j.ccr.2011.11.020

Stable IL-10: a new therapeutic that promotes tumor immunity

Cancer Cell. 2011 Dec 13;20(6):691-3. doi: 10.1016/j.ccr.2011.11.020.

Authors

Michele W L Teng¹, Phillip K Darcy, Mark J Smyth

Affiliation

¹ Cancer Immunology Program, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia.

PMID: 22172716
DOI: 10.1016/j.ccr.2011.11.020

Abstract

In this issue of Cancer Cell, Mumm et al. demonstrate that pegylated IL-10 increases CD8(+) T cell numbers, IFN-γ secretion, and cytotoxicity in established tumors, enhancing antigen presentation machinery and suppressing tumor growth. This approach may enhance T cell immune responses in cancers with reduced T cell infiltration.

Publication types

Comment
Research Support, Non-U.S. Gov't